Atherotech, Inc., a cardio-diagnostic company, announced that its VAP(R) Cholesterol Test is now included in Biophysical Corporation's newly released health assessment, BiophysicalCheck.

The announcement means that the VAP Test, with its unique ability to identify far more areas of risk than the standard lipid panel, will now be available in Biophysical's biomarker-based health assessment.

"The advanced cholesterol testing made possible by the VAP Test is a perfect and natural fit for Biophysical," said Atherotech Chief Medical Officer James Ehrlich, M.D. "It is certainly rewarding to be included in the offering of a company that brings so much expertise to the field of biomarkers and early detection."

The BiophysicalCheck is based on the technology used in the company's flagship test, the Biophysical250. This test has been called "The Ultimate Blood Test" by Scientific American and has been featured on highly-rated U.S. syndicated talk shows. The company anticipates adding the VAP Test to its other assessments later this year.

"The addition of the VAP Test strengthens even further our ability to detect cardiovascular disease at an earlier, more preventable stage," said George Rodgers, M.D., chief medical officer and president of Biophysical Corporation. "We're pleased to incorporate the VAP Test's expanded cholesterol testing into our biomarkers for the pre-symptomatic detection of disease."

The VAP Test directly measures LDL and has been shown to identify a far greater number of patients with lipid abnormalities than the standard lipid panel (cholesterol and triglyceride test). The test also reports 15 separate components versus four in the standard cholesterol test.